Christopher Helsen

Christopher Helsen has extensive experience in research and development in the field of immunotherapy. Christopher began their career in 1999, when they served in the German Air Force as a truck driver. In 2000, they were a Summer Student at HEXAL Pharmaceuticals. From 2005 to 2012, they worked at the University of Toronto as a Teaching Assistant and Doctoral Research in Biochemistry. During this time, they developed new technologies for cancer immunotherapy, adapted existing assays for enzyme activity, and mentored junior researchers. In 2012, they became a Postdoctoral Fellow at McMaster University, where they continued to develop new technologies for cancer immunotherapy. Since 2015, they have been the Executive Director R&D and Director Research and Development, Head of Platform Development at Triumvira Immunologics, Inc., where they have been inventing and optimizing the original cellular receptor (TAC) that has shown great attributes in pre-clinical trials.

Christopher Helsen has a long educational history. Christopher began their studies in 2000 at the Technical University of Munich, where they obtained a Diplom/ Master in Biochemistry by 2005. Christopher then went on to pursue a PhD at the University of Toronto from 2005 to 2011, specializing in Biochemistry and Yeast prions. In addition, they have obtained three certifications from LinkedIn in July 2022: Building Inclusive Work Communities, Diversity, Inclusion, and Belonging, and Inclusive Mindset.